TY - GEN T1 - Immunogenicity and Safety of Yellow Fever Vaccination for 102 HIV‐Infected Patients AU - Veit, Olivia AU - Niedrig, Matthias AU - Chapuis‐Taillard, Caroline AU - Cavassini, Matthias AU - Mossdorf, Erik AU - Schmid, Patrick AU - Bae, Hi‐Gung AU - Litzba, Nadine AU - Staub, Thomas AU - Hatz, Christoph AU - Furrer, Hansjakob AB - Background: Yellow fever vaccine (17DV) has been investigated incompletely in human immunodeficiency virus (HIV)–infected patients, and adequate immunogenicity and safety are of concern in this population. Methods: In the Swiss HIV Cohort Study, we identified 102 patients who received 17DV while they were HIV infected. We analyzed neutralization titers (NTs) after 17DV administration using the plaque reduction neutralization test. NTs of 1:10 were defined as reactive, and those of 1: KW - Adult KW - Humans KW - Female KW - Male KW - RNA KW - Antibodies KW - Viral/blood KW - Cohort Studies KW - Neutralization Tests KW - Viral Load KW - CD4 Lymphocyte Count KW - HIV Infections/immunology KW - Plaque Assay KW - Switzerland KW - Yellow Fever/immunology KW - Yellow Fever/prevention & control KW - Yellow Fever Vaccine/adverse effects KW - Yellow Fever Vaccine/immunology KW - 610 Medizin PY - 2009 LA - eng PB - Robert Koch-Institut VL - 48 DO - 10.1086/597006 ER -